



Toxicological Profile for Hexachlorocyclohexane (HCH)

Draft for Public Comment

January 2023



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
January 2023	Draft for public comment toxicological profile released
August 2005	Final toxicological profile released
July 1999	Final toxicological profile released
May 1994	Final toxicological profile released
December 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D. (Lead)
Melanie Buser, M.P.H.
Gaston Casillas, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Heather Carlson-Lynch, M.S., D.A.B.T.
Claire Heit, Ph.D.
Julie Melia, Ph.D., D.A.B.T.
Jennifer Rhoades, B.A.
Savannah Sierco, M.S.
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. Lisa Kamendulis, Ph.D.; Department of Environmental and Occupational Health; Indiana University Bloomington; Bloomington, Indiana
2. Russell C. Cattley, VMD, Ph.D., Dipl. ACVP, Fellow IATP; Tyler & Frances Young Professor of Pathology; Greene Hall; College of Veterinary Medicine; Auburn University, Alabama
3. Stephen M. Roberts, Ph.D.; Director, Center for Environmental & Human Toxicology; Professor, College of Veterinary Medicine; College of Medicine, and College of Public Health and Health Professions; University of Florida; Gainesville, Florida

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER ii

FOREWORD iii

VERSION HISTORY v

CONTRIBUTORS & REVIEWERS vi

CONTENTS vii

LIST OF FIGURES ix

LIST OF TABLES xi

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH 1

 1.1 OVERVIEW AND U.S. EXPOSURES 1

 1.2 SUMMARY OF HEALTH EFFECTS 1

 1.3 MINIMAL RISK LEVELS (MRLs) 7

CHAPTER 2. HEALTH EFFECTS 19

 2.1 INTRODUCTION 19

 2.2 DEATH 97

 2.3 BODY WEIGHT 100

 2.4 RESPIRATORY 103

 2.5 CARDIOVASCULAR 104

 2.6 GASTROINTESTINAL 107

 2.7 HEMATOLOGICAL 108

 2.8 MUSCULOSKELETAL 110

 2.9 HEPATIC 111

 2.10 RENAL 120

 2.11 DERMAL 120

 2.12 OCULAR 128

 2.13 ENDOCRINE 129

 2.14 IMMUNOLOGICAL 133

 2.15 NEUROLOGICAL 137

 2.16 REPRODUCTIVE 145

 2.17 DEVELOPMENTAL 155

 2.18 OTHER NONCANCER 179

 2.19 CANCER 183

 2.20 GENOTOXICITY 189

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS,
 CHEMICAL INTERACTIONS 196

 3.1 TOXICOKINETICS 196

 3.1.1 Absorption 197

 3.1.2 Distribution 199

 3.1.3 Metabolism 202

 3.1.4 Excretion 205

 3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 206

 3.1.6 Animal-to-Human Extrapolations 208

 3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY
 SUSCEPTIBLE 209

3.3	BIOMARKERS OF EXPOSURE AND EFFECT	212
3.3.1	Biomarkers of Exposure.....	213
3.3.2	Biomarkers of Effect.....	215
3.4	INTERACTIONS WITH OTHER CHEMICALS	215
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		219
4.1	CHEMICAL IDENTITY	219
4.2	PHYSICAL AND CHEMICAL PROPERTIES	220
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....		223
5.1	OVERVIEW	223
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	223
5.2.1	Production	224
5.2.2	Import/Export.....	225
5.2.3	Use	226
5.2.4	Disposal.....	227
5.3	RELEASES TO THE ENVIRONMENT	228
5.3.1	Air	228
5.3.2	Water.....	230
5.3.3	Soil	232
5.4	ENVIRONMENTAL FATE	232
5.4.1	Transport and Partitioning.....	232
5.4.2	Transformation and Degradation	238
5.5	LEVELS IN THE ENVIRONMENT.....	242
5.5.1	Air	245
5.5.2	Water.....	246
5.5.3	Sediment and Soil	256
5.5.4	Other Media	256
5.6	GENERAL POPULATION EXPOSURE.....	267
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	274
CHAPTER 6. ADEQUACY OF THE DATABASE.....		275
6.1	INFORMATION ON HEALTH EFFECTS.....	275
6.2	IDENTIFICATION OF DATA NEEDS	275
6.3	ONGOING STUDIES.....	285
CHAPTER 7. REGULATIONS AND GUIDELINES		286
CHAPTER 8. REFERENCES		289
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR HCH.....		B-1
APPENDIX C. FRAMEWORK FOR ATSDR’S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR HCH		C-1
APPENDIX D. USER’S GUIDE.....		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....		G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to γ -Hexachlorocyclohexane 3

1-2. Health Effects Found in Animals Following Oral Exposure to α -Hexachlorocyclohexane 3

1-3. Health Effects Found in Animals Following Oral Exposure to β -Hexachlorocyclohexane 4

1-4. Health Effects Found in Animals Following Oral Exposure to γ -Hexachlorocyclohexane 5

1-5. Health Effects Found in Animals Following Oral Exposure to Technical-Hexachlorocyclohexane 6

1-6. Summary of Sensitive Targets of α -Hexachlorocyclohexane (α -HCH) – Oral 12

1-7. Summary of Sensitive Targets of β -Hexachlorocyclohexane (β -HCH) – Oral 13

1-8. Summary of Sensitive Targets of γ -Hexachlorocyclohexane (γ -HCH) – Inhalation..... 14

1-9. Summary of Sensitive Targets of γ -Hexachlorocyclohexane (γ -HCH) – Oral..... 15

1-10. Summary of Sensitive Targets of Technical-Hexachlorocyclohexane (technical-HCH) – Oral 16

2-1. Overview of the Number of Studies Examining α -Hexachlorocyclohexane (α -HCH) Health Effects..... 23

2-2. Overview of the Number of Studies Examining β -Hexachlorocyclohexane (β -HCH) Health Effects..... 24

2-3. Overview of the Number of Studies Examining γ -Hexachlorocyclohexane (γ -HCH) Health Effects..... 25

2-4. Levels of Significant Exposure to γ -Hexachlorocyclohexane (Lindane) – Inhalation 28

2-5. Levels of Significant Exposure to α -Hexachlorocyclohexane – Oral..... 35

2-6. Levels of Significant Exposure to β -Hexachlorocyclohexane – Oral..... 44

2-7. Levels of Significant Exposure to γ -Hexachlorocyclohexane – Oral..... 72

2-8. Levels of Significant Exposure to δ - and Technical Hexachlorocyclohexane (HCH) – Oral 88

3-1. The Proposed Metabolism of Hexachlorocyclohexane 203

5-1. Number of NPL Sites with Hexachlorocyclohexane Contamination 223

6-1. Summary of Existing Health Effects Studies on α -Hexachlorocyclohexane By Route and Endpoint 276

6-2. Summary of Existing Health Effects Studies on β -Hexachlorocyclohexane By Route and Endpoint 277

6-3. Summary of Existing Health Effects Studies on γ -Hexachlorocyclohexane By Route and
Endpoint 278

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for α -Hexachlorocyclohexane	17
1-2. Minimal Risk Levels (MRLs) for β -Hexachlorocyclohexane	17
1-3. Minimal Risk Levels (MRLs) for γ -Hexachlorocyclohexane	18
2-1. Levels of Significant Exposure to γ -Hexachlorocyclohexane – Inhalation.....	26
2-2. Levels of Significant Exposure to α -Hexachlorocyclohexane – Oral.....	30
2-3. Levels of Significant Exposure to β -Hexachlorocyclohexane – Oral.....	39
2-4. Levels of Significant Exposure to γ -Hexachlorocyclohexane – Oral.....	48
2-5. Levels of Significant Exposure to δ - and Technical Hexachlorocyclohexane – Oral	79
2-6. Levels of Significant Exposure to γ -Hexachlorocyclohexane – Dermal.....	92
2-7. Levels of Significant Exposure to Technical Hexachlorocyclohexane – Dermal	94
2-8. Summary of Epidemiological Studies of β -Hexachlorocyclohexane (β -HCH) Exposure and Body weight Effects	101
2-9. Summary of Epidemiological Studies of β -Hexachlorocyclohexane Exposure and Cardiovascular Effects.....	105
2-10. Summary of Epidemiological Studies of β -Hexachlorocyclohexane Exposure and Hepatic Effects.....	111
2-11. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Renal Effects	122
2-12. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Endocrine Effects	130
2-13. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Immune Effects	134
2-14. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Neurological Effects.....	138
2-15. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Reproductive Effects	146
2-16. Summary of Epidemiological Studies of α -Hexachlorocyclohexane (HCH) Exposure and Developmental Effects	157
2-17. Summary of Epidemiological Studies of β -Hexachlorocyclohexane Exposure and Developmental Effects	159

2-18. Summary of Epidemiological Studies of γ -Hexachlorocyclohexane Exposure and Developmental Effects 167

2-19. Summary of Epidemiological Studies of δ -HCH and Total HCH Exposure and Developmental Effects 178

2-20. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Other Noncancer Effects 180

2-21. Summary of Epidemiological Studies Evaluating Possible Associations between Hexachlorocyclohexane Exposure and Risk of Selected Cancer Types..... 183

2-22. Genotoxicity of Hexachlorocyclohexane Isomers *In Vivo* 189

2-23. Genotoxicity of Hexachlorocyclohexane Isomers *In Vitro* 190

4-1. Chemical Identity of Hexachlorocyclohexane Isomers 219

4-2. Physical and Chemical Properties of Hexachlorocyclohexane Isomers 221

5-1. Facilities that Produce, Process, or Use γ -Hexachlorocyclohexane 224

5-2. Releases to the Environment from Facilities that Produce, Process, or Use Hexachlorobenzenes 229

5-3. HCH Emissions as Reported by the 2017 National Emission Inventory..... 230

5-4. Results of Experimental Bioaccumulation 236

5-5. Lowest Limit of Detection Based on Standards 243

5-6. Summary of Ambient Environmental Levels of HCH 243

5-7. Hexachlorocyclohexanes Levels in Water, Soil, and Air of National Priorities List (NPL) Sites ... 245

5-8. Outdoor Air Monitoring Data for Hexachlorocyclohexanes (HCHs)..... 247

5-9. Water Monitoring Data for Hexachlorocyclohexanes (HCHs) 251

5-10. Soil and Sediment Monitoring Data for Hexachlorocyclohexanes (HCHs)..... 257

5-11. Organism Monitoring Data for Hexachlorocyclohexanes (HCHs) 260

5-12. Geometric Mean of the Serum Concentration (ng/g) of β -Hexachlorocyclohexane (β -HCH) (2013–2014) and γ -Hexachlorocyclohexane (γ -HCH) (2011–2012) in the U.S. Population..... 270

6-1. Ongoing Studies on HCH 285

7-1. Regulations and Guidelines Applicable to Hexachlorocyclohexane (HCH) 286